2015-2017年回龙观地区疑似预防接种异常反应监测分析
|
摘要
目的对2015-2017年北京市昌平区回龙观地区AEFI监测情况进行分析,为疫苗安全监测工作提供科学依据。方法通过中国免疫规划信息管理系统收集回龙观地区2015-2017年AEFI个案。运用Excel和SPSS对AEFI病例数据进行整理,采用描述性分析方法,对AEFI分布特征和相关指标进行流行病学分析;对于剂次间率的比较采用■检验的统计方法。结果 2015-2017年回龙观地区共上报AEFI病例123例,报告病例中男64人(52%),女59人(48%);按发生原因主要为一般反应82例(66.7%),异常反应32例(26%);临床诊断主要为发热50例(40.65%),红肿硬结34例(27.64%);AEFI发生率前6位的疫苗分别是五联疫苗、麻风疫苗、流脑A群疫苗、乙脑疫苗、四联疫苗;接种后≤1d发生病例99例(80.49%)。结论回龙观地区AEFI报告敏感性逐渐增加,应继续加强AEFI监测工作。
Objective To analyze adverse events following immunization(AEFI)in Huilongguan from 2015 to 2017,so as to provide a scientific basis for vaccine safety surveillance.Methods Cases of AEFI in Huilongguan from 2015 to 2017 were collected through a national AEFI information system.Excel and SPSS software,descriptive analysis and ■ test were used to collate the cases,analyze the distribution characteristics and related indicators and compare the AEFI incidence rate of four dosages,respectively.Results From 2015 to 2017,123 cases of AEFI were reported in Huilongguan area,including 64 cases with male(52%)and 59 cases with a female(48%).According to the causes,82 AEFIs(66.7%)were common adverse reactions,and 32 AEFIs(26%)were serious adverse reactions.There were 50 cases of fever(66.7%)and 34 cases of erythema and sclerosis(26%).The top six vaccines in the incidence of AEFI were pentathlon vaccine,leprosy vaccine,meningococcal A vaccine,Japanese encephalitis vaccine and quadruple vaccine.99 cases(80.49%)occurred less than 1 day after injection.Conclusion The sensitivity of AEFI reports in Huilongguan is increasing gradually,and AEFI monitoring should continue to be strengthened.
Objective To analyze adverse events following immunization(AEFI)in Huilongguan from 2015 to 2017,so as to provide a scientific basis for vaccine safety surveillance.Methods Cases of AEFI in Huilongguan from 2015 to 2017 were collected through a national AEFI information system.Excel and SPSS software,descriptive analysis and ■ test were used to collate the cases,analyze the distribution characteristics and related indicators and compare the AEFI incidence rate of four dosages,respectively.Results From 2015 to 2017,123 cases of AEFI were reported in Huilongguan area,including 64 cases with male(52%)and 59 cases with a female(48%).According to the causes,82 AEFIs(66.7%)were common adverse reactions,and 32 AEFIs(26%)were serious adverse reactions.There were 50 cases of fever(66.7%)and 34 cases of erythema and sclerosis(26%).The top six vaccines in the incidence of AEFI were pentathlon vaccine,leprosy vaccine,meningococcal A vaccine,Japanese encephalitis vaccine and quadruple vaccine.99 cases(80.49%)occurred less than 1 day after injection.Conclusion The sensitivity of AEFI reports in Huilongguan is increasing gradually,and AEFI monitoring should continue to be strengthened.
引文
[1] 崔利伟.2005-2013年深圳市南山区疑似预防接种异常反应监测分析[J].现代预防医学,2015,42(16):3022-3024,3048.
[2] 卫生部.全国疑似预防接种异常反应监测方案[J].中国疫苗和免疫,2011(01):72-81.
[3] World Health Organization.Immunization safety surveillance:guidelines for immunization program managers on surveillance of adverse events following immunization[M].2nd ed.Manila:WHO Regional Office for the Western Pacific,2014.
[4] Di Pasquale A,Bonanni P,Gar?on N,et al.Vaccine safety evaluation:Practical aspects in assessing benefits and risks[J].Vaccine,2016,34(52):6672-6680.
[5] 叶家楷,李克莉,许涤沙,等.中国2015年疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2017,23(5):481-492,511.
[6] 王涛,杨俊英,范肖肖,等.2015-2016年北京市昌平区疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2017,23(3):317-321.
[7] 蔡乾春,王翠玲,吕海英,等.2007-2015年中山市疑似预防接种异常反应监测分析[J].现代预防医学,2017,44(16):3032-3036.
[8] 陈敏,梁亚琼,徐鹭,等.2013-2016年南京市疑似预防接种异常反应监测分析[J].现代预防医学,2017,44(23):4284-4288.
[9] 许濒月,周颖,韩真明,等.2011-2016年重庆市疑似预防接种异常反应监测分析[J].现代预防医学,2018,45(2):273-276,313.
[10] 叶家楷,李克莉,许涤沙,等.中国2014年疑似预防接种异常反应信息管理系统监测数据分析[J].中国疫苗和免疫,2016,22(2):125-137.
[11] 彭时辉,文海蓉,许波,等.275例吸附无细胞百白破疫苗疑似预防接种异常反应病例的流行病学分析[J].现代预防医学,2016,43(18):3413-3415,3456.
[2] 卫生部.全国疑似预防接种异常反应监测方案[J].中国疫苗和免疫,2011(01):72-81.
[3] World Health Organization.Immunization safety surveillance:guidelines for immunization program managers on surveillance of adverse events following immunization[M].2nd ed.Manila:WHO Regional Office for the Western Pacific,2014.
[4] Di Pasquale A,Bonanni P,Gar?on N,et al.Vaccine safety evaluation:Practical aspects in assessing benefits and risks[J].Vaccine,2016,34(52):6672-6680.
[5] 叶家楷,李克莉,许涤沙,等.中国2015年疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2017,23(5):481-492,511.
[6] 王涛,杨俊英,范肖肖,等.2015-2016年北京市昌平区疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2017,23(3):317-321.
[7] 蔡乾春,王翠玲,吕海英,等.2007-2015年中山市疑似预防接种异常反应监测分析[J].现代预防医学,2017,44(16):3032-3036.
[8] 陈敏,梁亚琼,徐鹭,等.2013-2016年南京市疑似预防接种异常反应监测分析[J].现代预防医学,2017,44(23):4284-4288.
[9] 许濒月,周颖,韩真明,等.2011-2016年重庆市疑似预防接种异常反应监测分析[J].现代预防医学,2018,45(2):273-276,313.
[10] 叶家楷,李克莉,许涤沙,等.中国2014年疑似预防接种异常反应信息管理系统监测数据分析[J].中国疫苗和免疫,2016,22(2):125-137.
[11] 彭时辉,文海蓉,许波,等.275例吸附无细胞百白破疫苗疑似预防接种异常反应病例的流行病学分析[J].现代预防医学,2016,43(18):3413-3415,3456.